z-logo
Premium
Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening
Author(s) -
Miller Connie H.,
Rice Anne S.,
Boylan Brian,
Payne Amanda B.,
Kelly Fiona M.,
Escobar Miguel A.,
Gill Joan,
Leissinger Cindy,
Soucie J. Michael
Publication year - 2015
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.24104
Subject(s) - medicine , prospective cohort study , titer , gastroenterology , immunology , antibody
Characteristics of inhibitors identified by prospective screening may differ from those detected clinically. In a prospective study at 17 hemophilia centers with central inhibitor measurement by Nijmegen‐Bethesda assay, 23 (2.8%) of 824 hemophilia A patients had new inhibitors detected: nine high‐titer inhibitors (HTI: 7 ≥ 5.0 NBU plus 2 of 2.6 and 3.4 NBU at immune tolerance induction initiation) and 14 low‐titer inhibitors (LTI: 0.5–1.9 NBU). HTI occurred at an earlier age (median 2 years, range 1–18, vs. median 11 years, range 2–61, P  = 0.016). Both HTI (22%) and LTI (43%) occurred in non‐severe patients. All HTI, but only 64% of LTI, were found to be FVIII‐specific by chromogenic Bethesda assay or fluorescence immunoassay (FLI), indicating a high rate of false‐positive LTI. Repeat specimens confirmed all HTI, 7/9 LTI, and 7/7 FVIII‐specific LTI. FLI results were similar between HTI and FVIII‐specific LTI; all included IgG 1 and IgG 4 subclasses. A comparable prospective study conducted from 1975 to 1979 at 13 U.S. centers found 31 (2.4%) new inhibitors among 1,306 patients. In both studies, one‐third of inhibitors occurred in non‐severe patients and one‐quarter after 150 exposure days (ED). Significant differences were seen in the age at which inhibitors occurred (median 16 years in the older study vs. 5 years currently, P  = 0.024) and in ED before inhibitor development, 10% in the older study and 43% currently study occurring within 20 ED, suggesting a temporal change in inhibitor development. Prospective screening detects inhibitors in patients of all severities, ages, and ED. Some LTI, however, are false positives. Am. J. Hematol. 90:871–876, 2015. © 2015 Wiley Periodicals, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here